These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32476465)

  • 41. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation.
    Shah SJ; Singer DE; Fang MC; Reynolds K; Go AS; Eckman MH
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006212. PubMed ID: 31707823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
    Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P
    Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Half-dose direct oral anticoagulation versus warfarin for atrial fibrillation following cardiac surgery.
    Hashim SW; Collazo S; Greco A; Mather JF; McKay RG
    J Cardiovasc Surg (Torino); 2024 Apr; 65(2):169-176. PubMed ID: 38470020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
    Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
    Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.
    Jaspers Focks J; Brouwer MA; Wojdyla DM; Thomas L; Lopes RD; Washam JB; Lanas F; Xavier D; Husted S; Wallentin L; Alexander JH; Granger CB; Verheugt FW
    BMJ; 2016 Jun; 353():i2868. PubMed ID: 27306620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L
    Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
    Ademi Z; Pasupathi K; Liew D
    Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study.
    Yasaka M; Umeyama M; Kataoka H; Inoue H
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105034. PubMed ID: 32807446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study-.
    Ogawa S; Shinohara Y; Kanmuri K
    Circ J; 2011; 75(8):1852-9. PubMed ID: 21670542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
    Alamneh EA; Chalmers L; Bereznicki LR
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
    Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J
    BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.
    Gomez-Lumbreras A; Cortes J; Giner-Soriano M; Quijada-Manuitt MA; Morros R
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):494-501. PubMed ID: 29792125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of direct oral anticoagulants in very elderly patients: a case report of apixaban in an ultracentenary patient.
    Manno G; Novo G; Corrado E; Coppola G; Novo S
    J Cardiovasc Med (Hagerstown); 2019 Jun; 20(6):403-405. PubMed ID: 30762659
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study.
    Bin Abdulhak AA; Kennedy KF; Gupta S; Giocondo M; Ramza B; Wimmer AP
    J Interv Card Electrophysiol; 2015 Nov; 44(2):91-6. PubMed ID: 26292959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.